How a sequential design would have affected the GAIN International Study of gavestinel in stroke.

Abstract

While planning the GAIN International Study of gavestinel in acute stroke, a sequential triangular test was proposed but not implemented. Before the trial commenced it was agreed to evaluate the sequential design retrospectively to evaluate the differences in the resulting analyses, trial durations and sample sizes in order to assess the potential of sequential procedures for future stroke trials. This paper presents four sequential reconstructions of the GAIN study made under various scenarios. For the data as observed, the sequential design would have reduced the trial sample size by 234 patients and shortened its duration by 3 or 4 months. Had the study not achieved a recruitment rate that far exceeded expectation, the advantages of the sequential design would have been much greater. Sequential designs appear to be an attractive option for trials in stroke.

• Authors: Kim Bolland, Amanda Weeks, John Whitehead, Kennedy R Lees,
• Journal: Cerebrovascular diseases (Basel, Switzerland) (Cerebrovasc Dis) Vol. 17 Issue 2-3 Pg. 111-7 ( 2004) ISSN: 1015-9770 [Print] Switzerland
• PMID: 14707409 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright 2004 S. Karger AG, Basel

Chemical References

• 3-(2-((phenylamino)carbonyl)ethenyl)-4,6-dichloroindole-2-carboxylic acid
• Excitatory Amino Acid Antagonists
• Indoles
• Neuroprotective Agents

Topics

• Acute Disease
• Clinical Trials, Phase III as Topic (methods)
• Excitatory Amino Acid Antagonists (therapeutic use)
• Humans
• Indoles (therapeutic use)
• Neuroprotective Agents (therapeutic use)
• Patient Selection
• Randomized Controlled Trials as Topic (methods)
• Retrospective Studies
• Stroke (drug therapy)
• Treatment Outcome